Preparative Regimens and Ageism  by Appelbaum, Frederick R.
From the
Wash
Correspon
MD,
Hutch
sion,
Seattl
Received A
 2011 Am
1083-8791
doi:10.101Preparative Regimens and Ageism
Frederick R. AppelbaumIn this issue of Biology of Blood and Marrow Trans-
plantation Alatrash and colleagues publish the results
of allogeneic hematopoietic cell transplantation in
79 patients with acute myeloid leukemia or myelodys-
plasia age 55 to 76 (median 5 58 years) using a condi-
tioning regimen of intravenous fludarabine (40 mg/
m2) and busulfan (130 mg/m2) (FLU/BU) each daily
from day 26 through day 23, with graft-vs-host dis-
ease prophylaxis of tacrolimus and methotrexate
(plus antithymocyte globulin with unrelated donors)
[1]. The results are quite reasonable with a 2-year
event-free survival of 44% for the entire group, and
an event-free survival of 68% for those transplanted
in first complete remission, 42% for second complete
remission, and 30% for those with active disease.
The authors conclude that for many patients,
FLU/BU, a so-called reduced toxicity myeloablative
regimen, is a reasonable choice, and that age alone
should not be the primary reason for exclusion of pa-
tients from receiving a myeloablative regimen.
The 2 major points of this paper are the supremacy
of FLU/BU as a preparative regimen and the defi-
ciencies of age as a marker for transplant tolerance.
More than a decade ago, investigators began asking
whether the potent immunosuppressive fludarabine
might be substituted for cyclophosphamide (CY) in
the widely used BU/CY preparative regimen, with
the hope that this might lead to less toxicity without
an increase in either graft rejection or tumor recur-
rence. Alatrash et al. [2] introduce the current paper
by citing an earlier retrospective study of theirs com-
paring FLU/BU with BU/CY. That study compared
148 patients who had been treated with BU/CY with
a more recent cohort treated with FLU/BU and con-
cluded that FLU/BU was superior with a lower inci-
dence of nonrelapse mortality, no increase in relapse
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while confirming decreased toxicity, have also seen
an increase in relapse rates with the FLU/BU regimen
compared with BU/CY [3]. In fact, at this year’s
American Society of Clinidal Oncology meeting, the
group from Seoul, Korea, presented the results of
a prospective randomized trial of FLU/BU vs
BU/CY as conditioning in 126 patients with leukemia
ormyelodysplasia [4]. They found similar rates of non-
relapse mortality with the 2 regimens, but a higher re-
lapse rate with FLU/BU, resulting in a statistically
superior overall survival with BU/CY (51% vs 36%).
The Korean study was not restricted to older patients,
but it does raise the possibility that patients with high-
risk leukemia able to tolerate full-dose BU/CY might
fare better with that regimen than with FLU/BU.
The second conclusion of the paper by Alatrash
et al., that age alone should not be the primary reason
for exclusion of patients from receiving amyeloablative
regimen, is less controversial. Numerous studies have
demonstrated that performance status and comorbid-
ities appear to be critical indicators of the ability
of patients to tolerate intensive preparative regimens,
and in fact, might outweigh the importance of age
alone [5-7]. We have recently made a similar
observation in patients with acute myeloid leukemia
undergoing induction chemotherapy; if one takes
into consideration performance status and certain
disease characteristics, age can be eliminated from
the model with only minimally impacted predictive
accuracy [8]. The problem, of course, is that age is sim-
ple and readily available, whereas models encompass-
ing performance status and comorbidities are more
complex and require greater effort to apply. However,
that is not an excuse for ignoring the more accurate in-
formation that suchmodels can provide. To rely totally
on chronologic age in making treatment decisions is
a form of prejudice akin to sexism or racism.ACKNOWLEDGMENTS
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